Antiproliferative effects of molecular iodine in cancers

Current Chemical Biology

Volumn 5, Issue 3, 2011, Pages 168-176

  Torremante, Pompilio Elio ^a   Rösner, Harald ^b  

^a Praxis für Gynäkologie und Geburtshilfe ^*  (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Antiproliferative; Apoptotic effects; Disruption of the mitochondrial transmembrane potential; Iodolactones; Malignant cell lines; Mitochondria mediated apoptosis; Molecular iodine

Indexed keywords

DELTA IODOLACTONE; IODINE; IODINE DERIVATIVE; THYROID HORMONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIA; BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CANCER PREVENTION; CONGENITAL HYPOTHYROIDISM; DIET; ENDEMIC DISEASE; HUMAN; HUMAN CELL; IODINE DEFICIENCY; MOLECULAR BIOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEAWEED; THYROID CANCER;

ANIMALIA; MAMMALIA;

EID: 80051721096     PISSN: None     EISSN: 18723136     Source Type: Journal    
DOI: 10.2174/187231311796764987     Document Type: Article

References (111)

1. Cohen BL. The origin of I in soil and the 129I problem. Health Phys 1985; 49: 279-85.
2. Küpper FC, Carpenter LJ, McFiggans GB, et al. Iodide accumulation provides kelp with an inorganic antioxidant impacting atmospheric chemistry. Proc Natl Acad Sci USA 2008; 105: 6954-8.
3. Nagataki S. The average of dietary iodine intake due to the ingestion of seaweeds is 1.2 mg/day in Japan. Thyroid 2008; 18: 667-68.
4. Funahashi H, Imai T, Tanaka Y, et al. Suppressive effect of iodine on DMBA-induced breast tumor growth in the rat. J Surg Oncol 1996; 61: 209-13.
5. García-Solís P, Alfaro Y, Anguiano B, et al. Inhibition of Nmethyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion. Mol Cell Endocrinol 2005; 236: 49-57.
6. Yang YJ, Nam SJ, Kong G, Kim MK. A case-control study on seaweed consumption and the risk of breast cancer. Br J Nutr 2010; 103: 1345-53.
7. Backer H, Hollowell J. Use of iodine for water disinfection: iodine toxicity and maximum recommended dose. Environ Health Perspect 2000; 108: 679-84.
8. Nicola JP, Basquin C, Portulano C, Reyna-Neyra A, Paroder M, Carrasco N. The Na+/I-symporter mediates active iodide uptake in the intestine. Am J Physiol Cell Physiol 2009; 296: C654-62.
9. A, Kopp P. Minireview: The sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid. Endocrinology 2009; 150: 1084-90.
10. Song Y, Driessens N, Costa M, et al. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab 2007; 92: 3764-73.
11. Gärtner R, Dugrillon A. From iodine deficiency to goiter. Pathophysiology of iodine deficiency goiter. Internist (Berl) 1998; 39: 566-73.
12. Lagorce JF, Thomes JC, Catanzano G, Buxeraud J, Raby M, Raby C. Formation of molecular iodine during oxidation of iodide by the peroxidase/H2O2 system. Implications for antithyroid therapy. Biochem Pharmacol 1991; 42 Suppl: S89-92.
13. Vitale M, Di Matola T, D'Ascoli F, et al. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 2000; 141: 598-605.
14. Pisarev MA, Krawiec L, Juvenal GJ, et al. Studies on the goiter inhibiting action of iodolactones. Eur J Pharmacol 1994; 258: 33-37.
15. Gärtner R, Rank P, Ander B. The role of iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (Athens) 2010; 9: 60-66.
16. Thomasz L, Oglio R, Randi AS, et al. Biochemical changes during goiter induction by methylmercaptoimidazol and inhibition by delta-iodolactone in rat. Thyroid 2010; 20: 1003-13.
17. Turk J, Henderson WR, Klebanoff SJ, Hubbard WC. Iodination of arachidonic acid mediated by eosinophil peroxidase, myeloperoxidase and lactoperoxidase. Identification and comparison of products. Biochim Biophys Acta 1983; 751: 189-200.
18. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173-82.
19. McElhinney B, Poynter ME, Shrivastava P, Hazen SL, Janssen-Heininger YM. Eosinophil peroxidase catalyzes JNK-mediated membrane blebbing in a Rho kinase-dependent manner. J Leukoc Biol 2003; 74: 897-907.
20. Klebanoff SJ, Shepard CC. Toxic effect of the peroxidasehydrogen peroxide-halide antimicrobial system on Mycobacterium leprae. Infect Immun 1984; 44: 534-36.
21. Everse KE, Lin H, Stuyt EL, Brady JC, Buddingh F, Everse J. Antitumour activity of peroxidases. Br J Cancer 1985; 51: 743-46.
22. Combs SH, Morgan CD, Everse J. Antitumor activity of an immobilized peroxidase system against murine Ehrlich ascites is mediated by the immune system. Proc Soc Exp Biol Med 1993; 204: 306-11.
23. Jong EC, Klebanoff SJ. Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system. J Immunol 1980; 124: 1949-53.
24. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
25. Su JY, Xu XH, Zeng LM, Wang CJ. New iodolactone from Laurencia majuscula. Gaodeng Xuexiao Huaxue Xuebao 1997; 18: 1333-1334.
26. Josefsson M, Evilevitch L, Weström B, Grunditz T, Ekblad E. Sodium-iodide symporter mediates iodide secretion in rat gastric mucosa in vitro. Exp Biol Med (Maywood) 2006; 231: 277-81.
27. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998; 83: 1746-51.
28. Wapnir IL, Goris M, Yudd A, et al. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res 2004; 10: 4294-302.
29. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13: 797-826.
30. Zhang Z. Regulation of sodium iodide symporter expression/ function and generation of NISLucYFP/wt knock-in mouse. Dissertation The Ohio State University 2007; Available from: http://gradworks.umi.com/32/86/3286792.html
31. Shennan DB. Iodide transport in lactating rat mammary tissue via a pathway independent from the Na+/I- cotransporter: evidence for sulfate/iodide exchange. Biochem Biophys Res Commun 2001; 280: 1359-63.
32. Rillema JA, Hill MA. Pendrin transporter carries out iodide uptake into MCF-7 human mammary cancer cells. Exp Biol Med (Maywood) 2003; 228: 1078-82.
33. Arroyo-Helguera O, Anguiano B, Delgado G, Aceves C. Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr Relat Cancer 2006; 13: 1147-58.
34. Gaertner FC, Rohde F, Mueller J, Blechert B, Janssen KP, Essler M. Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma. Int J Cancer 2009; 125: 2783-91.
35. Eskin BA, Anjum W, Abraham GE, Stoddard F, Prestrud AA, Brooks AD. Identification of breast cancer by differences in urinary iodine. Proc Amer Assoc Cancer Res 2005; 46: Abstract 2150.
36. Gulaboglu M, Yildiz L, Celebi F, Gul M, Peker K. Comparison of iodine contents in gastric cancer and surrounding normal tissues. Clin Chem Lab Med 2005; 43: 581-84.
37. Goldfeder A. Der Metabolismus von Kohlehydraten, Calcium und Jod bei experimentellen bösartigen Geschwülsten. J Cancer Res Clin Oncol 1928; 27: 503-36.
38. Eskin BA, Grotkowski CE, Connolly CP, Ghent WR. Different tissue responses for iodine and iodide in rat thyroid and mammary glands. Biol Trace Elem Res 1995; 49: 9-19.
39. Park KG, Chetty U, Scott W, Miller W. The activity of locally applied cytotoxics to breast cancer cells in vitro. Ann R Coll Surg Engl 1991; 73: 96-69.
40. Stoddard FR 2nd, Brooks AD, Eskin BA, Johannes GJ. Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci 2008; 5: 189-96.
41. Iwamoto KS. The Mechanistic Role of Iodine in Breast Carcinogenesis. Available from: www.stormingmedia.us/73/7326/A732-644.html
42. Wu JS, Pfister SM, Ruiz MB, Connett JM, Fleshman JW. Local treatment of abdominal wound reduces tumor implantation. J Surg Oncol 1998; 69: 9-13.
43. Neuhaus SJ, Watson DI, Ellis T, Rofe AM, Jamieson GG. Influence of cytotoxic agents on intraperitoneal tumor implantation after laparoscopy. Dis Colon Rectum 1999; 42: 10-15.
44. Zhang L, Sharma S, Zhu LX, et al. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 2003; 63: 5065-72.
45. Fanning NF, Manning BJ, Buckley J, Redmond HP. Iodinated contrast media induce neutrophil apoptosis through a mitochondrial and caspase mediated pathway. Br J Radiol 2002; 75: 861-73.
46. Boeynaems JM, Reagan D, Hubbard WC. Lactoperoxidasecatalyzed iodination of arachidonic acid: formation of macrolides. Lipids 1981; 16: 246-49.
47. Rösner H, Torremante P, Möller W, Gärtner R. Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGFsignaling, but evidence for apoptosis. Exp Clin Endocrinol Diabetes 2010; 118: 410-19.
48. Arroyo-Helguera O, Rojas E, Delgado G, Aceves C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6- iodolactone mediates apoptotic effects. Endocr Relat Cancer 2008; 15: 1003-11.
49. Anguiano B, García-Solís P, Delgado G, Aceves Velasco C. Uptake and gene expression with antitumoral doses of iodine in thyroid and mammary gland: evidence that chronic administration has no harmful effects. Thyroid 2007; 17: 851-59.
50. Dugrillon A, Gärtner R. Delta-Iodolactones decrease epidermal growth factor-induced proliferation and inositol-1,4,5-trisphosphate generation in porcine thyroid follicles--a possible mechanism of growth inhibition by iodide. Eur J Endocrinol 1995; 132: 735-43.
51. Liu XH, Chen GG, Vlantis AC, Tse GM, van Hasselt CA. Iodine induces apoptosis via regulating MAPKs-related p53, p21, and BclxL in thyroid cancer cells. Mol Cell Endocrinol 2010; 320: 128-35.
52. Rachev RR, Dimitrov OA, Philipova EH, Penchev PB, Dekov I. Effects of iodine upon the structure and function of mitochondria. J Bioenerg Biomembr 1973; 5: 17-25.
53. Rall JE, Michel R, Roche J, Michel O, Varrone S. Action and metabolism of thyroid hormones and iodine-donating substances. I. Liver mitochondria. J Biol Chem 1963; 238: 1848-54.
54. Rachev RR. Effect of inorganic iodine on oxidative phosphorylation in brain and kidney mitochondria of normal and hyperthyroid rabbits. Bull Exp Biol Med 1966; 61: 53-55.
55. Cunningham LW, Nuenke BJ. Physical and chemical studies of a limited reaction of iodine with proteins. J Biol Chem 1959; 234: 1447-51.
56. Varrone S, Consiglio E, Covelli I. The nature of inhibition of mitochondrial malate dehydrogenase by thyroxine, iodine cyanide and molecular iodine. Eur J Biochem 1970; 13: 305-12.
57. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ 2006; 13: 1396-402.
58. Shrivastava A, Tiwari M, Sinha RA, et al. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem 2006; 281: 19762-71.
59. Chen FY, Han MS, Choon NO. Intracellular thiol depletion causes mitochondrial permeability transition in Ebselen-induced apoptosis. Arch Biochem Biophys 2000; 380: 319-30.
60. Hall AG. The role of gluthadione in the regulation of apoptosis. Eur J Clin Invest 1999; 29: 238-45.
61. Kirihara M, Asaia Y, Ogawaa S, Noguchia T, Hatanoa A, Hiraib Y. A mild and environmentally benign oxidation of thiols to disulfides. Synthesis 2007; 21: 3286-89.
62. Aoshiba K, Yasui S, Nishimura K, Nagai A. Thiol depletion induces apoptosis in cultured lung fibroblasts. Am J Respir Cell Mol Biol 1999; 21: 54-64.
63. Filomeni G, Rotilio G, Ciriolo MR. Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP-kinase pathway. The FASEB J 2003; 17: 64-66.
64. Honda T, Coppola S, Ghibelli L, Cho SH, Kagawa S, Spurgers KB, et al. GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther 2004; 11: 249-55.
65. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-606.
66. Zhang R, Al-Lamki R, Bai L, et al. Thioredoxin-2 inhibits mitochondria- located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res 2004; 94: 1483-91.
67. He M, Cai J, Go YM, et al. Identification of thioredoxin-2 as a regulator of the mitochondrial permeability transition. Toxicol Sci 2008; 105: 44-50.
68. Aceves C, García-Solís P, Arroyo-Helguera O, Vega-Riveroll L, Delgado G, Anguiano B. Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Mol Cancer 2009; 8: 33.
69. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-11.
70. Menon SG, Coleman MC, Walsh SA, Spitz DR, Goswami PC. Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G(1)- delay. Antioxid Redox Signal 2005; 7: 711-18.
71. Bae JY, Ahn SJ, Han W, Noh DY. Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 2007; 101: 1038-45.
72. Upadhyay G, Singh R, Sharma R, Balapure AK, Godbole MM. Differential action of iodine on mitochondria from human tumoraland extra-tumoral tissue in inducing the release of apoptogenic proteins. Mitochondrion 2002; 2: 199-210.
73. Davis W Jr, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 2001; 296: 1-6
74. Marasinghe GP, Sander IM, Bennett B, et al. Structural studies on a mitochondrial glyoxalase II. J Biol Chem 2005; 280: 40668-75.
75. Holmgren A, Johansson C, Berndt C, Lönn ME, Hudemann C, Lillig CH. Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans 2005; 33: 1375-7.
76. Rulli A, Carli L, Romani R, et al. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 2001; 66: 67-72.
77. Cook JA, Pass HI, Iype SN, et al. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 1991; 51: 4287-94.
78. Powis G, Kirkpatrick DL, Angulo M, Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 1998; 111-12: 23-34.
79. Choi JH, Ha J, Park JH, et al. Costunolide triggers apoptosis in human leukemia U937 cells by depleting intracellular thiols. Jpn J Cancer Res 2002; 93: 1327-33.
80. Unahara Y, Kojima-Yuasa A, Higashida M, et al. Cellular thiol status-dependent inhibition of tumor cell growth via modulation of p27(kip1) translocation and retinoblastoma protein phosphorylation by 1'-acetoxychavicol acetate. Amino Acids 2007; 33: 469-76.
81. Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha aopototic signaling. J Biol Chem 2001; 276: 12035-40.
82. Gärtner R, Rank P, Ander B. The role of iodine and deltaiodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (Athens) 2010; 9: 60-6.
83. Hudlicky T, Rinner U, Finn KJ, Ghiviriga I. Reactions of indole derivatives with oxiranes and aziridines on silica. Synthesis of betacarbolin- 1-one mimic of pancratistatin. J Org Chem 2005; 70: 3490-99.
84. Thrall KD, Bull RJ. Differences in the distribution of iodine and iodide in the Sprague-Dawley rat. Fundam Appl Toxicol 1990; 15: 75-81.
85. Thrall KD, Bull RJ, Sauer RL. Distribution of iodine into blood components of the Sprague-Dawley rat differs with the chemical form administered. J Toxicol Environ Health 1992; 37: 443-9.
86. Thrall KD, Sauer RL, Bull RJ. Evidence of thyroxine formation following iodine administration in Sprague-Dawley rats. J Toxicol Environ Health 1992; 37: 535-48.
87. Sherer TT, Thrall KD, Bull RJ. Comparison of toxicity induced by iodine and iodide in male and female rats. J Toxicol Environ Health 1991; 32: 89-101.
88. Robison LM, Sylvester PW, Birkenfeld P, Lang JP, Bull RJ. Comparison of the effects of iodine and iodide on thyroid function in humans. J Toxicol Environ Health A 1998; 55: 93-106.
89. Tham DM, Whitin JC, Kim KK, Zhu SX, Cohen HJ. Expression of extracellular glutathione peroxidase in human and mouse gastrointestinal tract. Am J Physiol 1998; 275: G1463-71.
90. Kelly FJ. Glutathione content of the small intestine: regulation and function. Br J Nutr 1993; 69: 589-96.
91. Peters WH, Roelofs HM, Nagengast FM, van Tongeren JH. Human intestinal glutathione S-transferases. Biochem J 1989; 257: 471-6.
92. Schultze MO, Elvehjem CA. Studies on the glutathione content of the blood in nutritional anemia. J Biol Chem 1936; 116: 711-6.
93. Stanbury JB. Iodine metabolism and physiological aspects of endemic goitre. Bull World Health Organ 1958; 18: 201-15.
94. Taurog A, Howells EM, Nachimson HI. Conversion of iodate to iodide in vivo and in vitro. J Biol Chem 1966; 241: 4686-93.
95. Shanbrom E. Iodine-iodide treatment of red blood cells. PATENTSCOPE ® WO/1994/006289 1994; Available from: http://www.wipo.int/pctdb/en/wo.jsp?IA=WO1993004731&wo=1993004731&DISPLAY=DESC
96. ® WO/1993/017693 1993; Available from: http://www.wipo.int/pctdb/en/wo.jsp?WO=1993017693
97. Matthaes P. Ueber die preoperative Vorbehandlung hyperthyreoter Strumen mit Endojodin. Langenbecks Arch Chir 1970; 328: 78-90.
98. Westermann HH. Anorganisches Jod zur Behandlung thyreotoxischer Krisen. Klinische Wochenschrift 1941; 20: 1124-1127.
99. ® Solution (10% povidone iodine) 2005; Available from: http://www.safety.vanderbilt.edu/-pdf/hcs_msds/betadine_solution%207_05.pdf
100. Heinrich HC, Gabbe EE, Nass WP, Becker K. Untersuchungen zum Stoffwechselverhalten von J131-Polyvinylpyrrolidon im menschlichen Körper. Klinische Wochenschrift 1966;44: 488-493.
101. Zhu Z, Li Y, Li X, et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)- b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 2010; 142: 438-46.
102. Li X, Li R, Qian X, et al. Superior antitumor efficiency of cisplatin- loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 2008; 70: 726-34.
103. Yoshioka Y, Tsutsumi Y, Mukai Y, et al. Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleen. J Biomed Mater Res A 2004; 70: 219-23.
104. Taşdelen B, Kayaman-Apohan N, Misirli Z, Güven O, Baysal BM. Preparation, characterization, and drug-release properties of poly(N- isopropylacrylamide) microspheres having poly(itaconic acid) graft chains. J Appl Polym Sci 2005; 97: 1115-1124.
105. Sabracos L, Romanou S, Dontas I, Coulocheri S, Ploumidou K, Perrea D. The in vitro effective antiviral action of povidone-iodine (PVP-I) may also have therapeutic potential by its intravenous administration diluted with Ringer's solution. Med Hypotheses 2007; 68: 272-4.
106. Richards, James C. (Sudbury, MA, US). Method for in situ Generation of Molecular Iodine on Mucus Membranes Using Nanoparticles 2010; Available from: http://www.freepatentsonline.com/y-2010/0247656.html#Abstract
107. Coleman, M., P. Babb, P. Damiecki. Cancer Survival Trends in England and Wales, 1971-1995: Deprivation and NHS Region. Vol. 1999: TSO.
108. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009; 10: 35-69.
109. Richards MA. Trends and inequalities in survival for 20 cancers in England and Wales 1986-2001: population-based analyses and clinical commentaries. Foreword. Br J Cancer 2008; 99 Suppl 1: S1.
110. Office for National Statistics (ONS), Survival Rates in England, patients diagnosed 2001-2006 followed up to 2007.
111. American Cancer Society 2011. Available from: http://www.-cancer.org/cancer/pancreaticcancer/detailedguide/pancreaticcancer-survival-rates